Vivendi SE's Canal+, a French premium television channel, is set to issue a firm intention to acquire remaining shares in MultiChoice, an African entertainment company. For this, the former was given extra time to make a mandatory offer for the takeover.
Extended Deadline for Bid
According to Tech Central, Canal Plus has an additional 25 days to make an offer to shareholders of the MultiChoice Group. The new deadline has been moved to no later than April 8, and this was confirmed on Monday, March 4.
Canal Plus said via a statement to its shareholders that it received an extension from the Takeover Regulation Panel (TRP) to make the mandatory bid. The additional time comes after the TRP determined that the French TV channel had triggered a mandatory offer requirement under South African law after having purchased more than 35% of MultiChoice's shares.
"Canal+ respects the decision taken by the Panel, and will comply with it," Reuters quoted the media group as saying in a statement. "On this basis, Canal+ confirms that it has applied for and received from the Panel an exemption from adhering to the timing requirements."
Rejection of First Bid Offer
Canal Plus is already the largest shareholder in MultiChoice, and last month, it placed an offer to buy the remaining stake in the company for 105 rand per share. However, the latter did not accept the offer, stating the price given considerably undervalued the company.
Meanwhile, Business Tech reported that MultiChoice approached the TRP to make a decision on the buyout bid from the TV channel. But then, despite being issued a compliance notice for the public manner where it approached the TRP, the company did not get its answer from the panel, and because of this, Canal+ will have to make a mandatory offer.
Photo by: MultiChoice Media Room


Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Washington Post Publisher Will Lewis Steps Down After Layoffs
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 



